cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Immunitybio Inc
11 own
5 watching
Current Price
$0
$-0.15
(-3.26%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
1,781.35M
52-Week High
52-Week High
7.85
52-Week Low
52-Week Low
2.6
Average Volume
Average Volume
0.48M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization1,781.35M
icon52-Week High7.85
icon52-Week Low2.6
iconAverage Volume0.48M
iconDividend Yield--
iconP/E Ratio--
What does the Immunitybio Inc do?
ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The company also develops therapeutic agents, which are in Phase II or III clinical trial for the treatment of liquid and solid tumors, including bladder, pancreatic, and lung cancers, as well as pathogens as SARS-CoV-2 and HIV. It has collaboration agreements with National Cancer Institute, National Institute of Deafness and Communication Disorders, and Amyris, Inc.; and license agreements with CytRx Corporation, EnGeneIC Pty Limited, GlobeImmune, Inc., and Infectious Disease Research Institute, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., Sorrento Therapeutics, Inc., and Viracta Therapeutics, Inc. The company was founded in 2014 and is based in San Diego, California.
Read More
How much money does Immunitybio Inc make?
News & Events about Immunitybio Inc.
Business Wire
15days ago
ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced positive results in its fully-enrolled metastatic pancreatic cancer study in third-line or greater subjects (QUILT 88) showing that the overall survival rate for patients continues to be double compared to...
Business Wire
1month ago
ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced that it has executed financing to provide further working capital and support its ongoing business operations. The Company entered into a securities purchase agreement for a registered direct offering with a...
Business Wire
2 months ago
ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, announced today that the company will be participating in the 34th Annual Piper Sandler Healthcare Conference, which is taking place in New York City, November 29 - December 1, 2022. Details of the presentation can be found...
Tickeron - Stocks
5 months ago
This is a signal that IBRX's price trend could be reversing, and it may be an opportunity to buy the stock or explore call options...
PR Newswire
5 months ago
Bladder Cancer Clinical Trial Pipeline Insights Featuring 100+ Companies | DelveInsight Bladder Cancer Clinical Trial Pipeline Insights Featuring 100+ Companies | DelveInsight PR Newswire LAS VEGAS, Aug. 23, 2022 DelveInsight's bladder cancer pipeline report depicts a robust space with 100+ active...
Frequently Asked Questions
Frequently Asked Questions
What is Immunitybio Inc share price today?
plus_minus_icon
Can Indians buy Immunitybio Inc shares?
plus_minus_icon
How can I buy Immunitybio Inc shares from India?
plus_minus_icon
Can Fractional shares of Immunitybio Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Immunitybio Inc stocks?
plus_minus_icon
What is today’s traded volume of Immunitybio Inc?
plus_minus_icon
What is today’s market capitalisation of Immunitybio Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Immunitybio Inc?
plus_minus_icon
What percentage is Immunitybio Inc down from its 52-Week High?
plus_minus_icon
What percentage is Immunitybio Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$0
$-0.15
(-3.26%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00